Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD

Conditions:   HER2-positive Breast Cancer;   LMD Interventions:   Drug: Tucatinib 150 MG;   Drug: Trastuzumab;   Drug: Capecitabine;   Radiation: Brain & Spinal Radiation Sponsors:   Sunnybrook Health Sciences Centre;   Seagen Inc.;   Viatris Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials